Unnafected female carriers of BRCA1 and BRCA2 pathogenic/likely pathogenic variants (P/LPVs) are at higher risk of breast cancer (BC) and ovarian cancer (OC). In the retrospective single-institution study in the Czech Republic, we analyzed the rate, longitudinal trends, and effectiveness of prophylactic risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) on the incidence of BC and OC in BRCA1/2 carriers diagnosed between years (y) 2000 to 2020. The study included 496 healthy female BRCA1/2 carriers. The median follow-up was 6.0 years. RRM was performed in 156 (31.5%, mean age 39.3 y, range 22-61 y) and RRSO in 234 (47.2%, mean age 43.2 y, range 28-64 y) BRCA1/2 carriers. A statistically significant increase of RRM (from 12% to 29%) and RRSO (from 31% to 42%) was observed when comparing periods 2005-2012 and 2013-2020 (p < 0.001). BC developed in 15.9% of BRCA1/2 carriers without RRM vs. 0.6% of BRCA1/2 carriers after RRM (HR 20.18, 95% CI 2.78- 146.02; p < 0.001). OC was diagnosed in 4.3% vs. 0% of BRCA1/2 carriers without vs. after RRSO (HR not defined due to 0% occurrence in the RRSO group, p < 0.001). Study results demonstrate a significant increase in the rate of prophylactic surgeries in BRCA1/2 healthy carriers after 2013 and the effectiveness of RRM and RRSO on the incidence of BC and OC in these populations.

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University náměstí Sítná 3105 272 01 Kladno Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital U Nemocnice 499 2 128 08 Prague Czech Republic

Department of Oncology Nitra Faculty Hospital Špitálska 6 949 01 Nitra Slovakia

Department of Surgery Sunderby Hospital Sjukhusvägen 10 954 42 Sunderbyn Sweden

Faculty of Medicine Masaryk University 601 77 Kamenice 5 625 00 Brno Czech Republic

International Clinical Research Center Pekařská 664 53 602 00 Brno Czech Republic

See more in PubMed

Kwon J.S., Gutierrez-Barrera A.M., Young D., Sun C.C., Daniels M.S., Lu K.H., Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J. Clin. Oncol. 2010;28:4214–4220. PubMed

Begg C.B., Haile R.W., Borg A., Malone K.E., Concannon P., Thomas D.C., Langholz B., Bernstein L., Olsen J.H., Lynch C.F., et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299:194–201. doi: 10.1001/jama.2007.55-a. PubMed DOI PMC

Kuchenbaecker K.B., Hopper J.L., Barnes D.R., Phillips K.A., Mooij T.M., Roos-Blom M.J., Jervis S., van Leeuwen F.E., Milne R.L., Andrieu N., et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402–2416. doi: 10.1001/jama.2017.7112. PubMed DOI

Mavaddat N., Peacock S., Frost D., Ellis S., Platte R., Fineberg E., Gareth Evans D., Izatt L., Eekes ARm Adlard J., Davidson R., et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 2013;105:812–822. doi: 10.1093/jnci/djt095. PubMed DOI

Antoniou A., Pharoah P.D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003;72:1117–1130. doi: 10.1086/375033. PubMed DOI PMC

Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Kwan E., Jack E., Vesprini D.J., Kuperstein G., Abrahamson J.L., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001;68:700–710. doi: 10.1086/318787. PubMed DOI PMC

Pohlreich P., Zikan M., Stribrna J., Kleibl Z., Janatova M., Kotlas J., Zidovska J., Novotny J., Petruzelka L., Szabo C., et al. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res. 2005;7:R728–R736. doi: 10.1186/bcr1282. PubMed DOI PMC

Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., Garber J.E., Cramer D.W., Crum C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006;30:230–236. doi: 10.1097/01.pas.0000180854.28831.77. PubMed DOI

Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Goggins M., Hutton M.L., et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021;19:77–102. doi: 10.6004/jnccn.2021.0001. PubMed DOI

Finch A.P., Lubinski J., Møller P., Singer C.F., Karlan B., Senter L., Rosen B., Maehle L., Ghadirian P., Narod S.A., et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 2014;32:1547–1553. doi: 10.1200/JCO.2013.53.2820. PubMed DOI PMC

Sessa C., Balmaña J., Bober S.L., Cardoso M.J., Colombo N., Curigliano G., Domchek S.M., Evans D.G., Fischerova D., Paluch-Shimon S., et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann. Oncol. 2023;34:33–47. doi: 10.1016/j.annonc.2022.10.004. PubMed DOI

Woodward E., Sleightholme H., Considine A., Williamson S., McHugo J., Cruger D. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population-risk women is ineffective. BJOG Int. J. Obstet. Gynaecol. 2007;114:1500–1509. PubMed

Carbine N.E., Lostumbo L., Wallace J., Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 2018;4:CD002748. doi: 10.1002/14651858.CD002748.pub4. PubMed DOI PMC

Heemskerk-Gerritsen B.A.M., Jager A., Koppert L.B., Obdeijn A.I., Collée M., Meijers-Heijboer H.E.J., Jenner D.J., Oldenburg H.S.A., van Engelen K., de Vries J., et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2019;177:723–733. PubMed PMC

Ludwig K.K., Neuner J., Butler A., Geurts J.L., Kong A.L. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am. J. Surg. 2016;212:660–669. doi: 10.1016/j.amjsurg.2016.06.010. PubMed DOI

Heemskerk-Gerritsen B.A., Seynaeve C., van Asperen C.J., Ausems M.G., Collée J.M., van Doorn H.C., Gomez Garcia E.B., Kets C.M., van Leeuwen F.E., Meijers-Heijboer H.E., et al. Hereditary Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: Revisiting the evidence for risk reduction. J. Natl. Cancer Inst. 2015;107:djv033. doi: 10.1093/jnci/djv033. PubMed DOI

Kotsopoulos J., Huzarski T., Gronwald J., Singer C.F., Moller P., Lynch H.T., Armel S., Karlan B., Foulkes W.D., Neuhausen S.L., et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2016;109:djw177. PubMed PMC

Stjepanovic N., Villacampa G., Nead K.T., Torres-Esquius S., Melis G.G., Nathanson K.L., Teule A., Brunet J., YCajal T.R., Llort G., et al. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. Eur. J. Cancer. 2020;132:53–60. PubMed

Skytte A.B., Gerdes A.M., Andersen M.K., Sunde L., Brøndum-Nielsen K., Waldstrøm M., Kølvraa S., Crüger D. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA1/2 mutation carriers: Uptake and timing. Clin. Genet. 2010;77:342–349. PubMed

This P., De La Rochefordiere A., Savignoni A., Falcon M.C., Tardivon A., Thibault F., Alran S., Fourchotte V., Fitoussi A., Couturaud B., et al. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: Patient choices and outcome. Fam. Cancer. 2012;11:473–482. PubMed

Collins I.M., Milne R.L., Weideman P.C., McLachlan S.A., Friedlander M.L., Cuningham K., Hopper J.L., Phillips K.A. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. Med. J. Aust. 2013;199:680–683. PubMed

Metcalfe K., Eisen A., Senter L., Armel S., Bordeleau L., Meschino W.S., Pal T., Lynch H.T., Tung N.M., Kwong A., et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer. 2019;121:15–21. PubMed PMC

Pohlreich P., Stribrna J., Kleibl Z., Zikan M., Kalbacova R., Petruzelka L., Konopasek B. Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic. Med. Princ. Pract. 2003;12:23–29. doi: 10.1159/000068163. PubMed DOI

Pohlreich P., Stribrna J., Ticha I., Soukupova J., Kleibl Z., Zikan M., Zimovjanova M., Kotlas J., Panczak A. Predisposing genes in hereditary breast and ovarian cancer in the Czech Republic. Eur. J. Cancer Suppl. 2010;8:16.

Ticha I., Kleibl Z., Stribrna J., Kotlas J., Zimovjanova M., Mateju M., Zikan M., Pohlreich P. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: High proportion of population-specific alterations in BRCA1 gene. Breast Cancer Res. Treat. 2010;124:337–347. PubMed

Soukupova J., Zemankova P., Lhotova K., Janatova M., Borecka M., Stolarova L., Lhota F., Foretova L., Machackova E., Stranecky V., et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS ONE. 2018;13:e0195761. doi: 10.1371/journal.pone.0195761. PubMed DOI PMC

Lhota F., Zemankova P., Kleiblova P., Soukupova J., Vocka M., Stranecky V., Janatova M., Hartmannova H., Hodanova K., Kmoch S., et al. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients. Clin. Genet. 2016;90:324–333. doi: 10.1111/cge.12748. PubMed DOI

Singh N., Gilks C.B., Wilkinson N., McCluggage W.G. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67:331–337. doi: 10.1111/his.12651. PubMed DOI

Rosenthal A.N., Fraser L.S.M., Philpott S., Manchanda R., Burnell M., Badman P., Hadwin R., Rizzuto I., Benjamin E., Jacobs I.J., et al. United Kingdom Familial Ovarian Cancer Screening Study collaborators. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J. Clin. Oncol. 2017;35:1411–1420. doi: 10.1200/JCO.2016.69.9330. PubMed DOI PMC

Evans D.G., Gandhi A., Wisely J., Clancy T., Woodward E.R., Harvey J., Highton L., Murphy J., Barr L., Howell A., et al. Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. Breast. 2021;60:45–52. doi: 10.1016/j.breast.2021.08.015. PubMed DOI PMC

Ložar T., Žgajnar J., Perhavec A., Blatnik A., Novaković S., Krajc M. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia. Eur. J. Surg. Oncol. 2021;47:1900–1906. PubMed

Evans D.G., Wisely J., Clancy T., Lalloo F., Wilson M., Johnson R., Duncan J., Barr L., Gandhi A., Howell A. Longer term effects of the Angelina Jolie effect: Increased risk-reducing mastectomy rates in BRCA1/2 carriers and other high-risk women. Breast Cancer Res. 2015;17:17–18. PubMed PMC

Lee J., Kim S., Kang E., Park S., Kim Z., Lee M.H. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J. Breast Cancer. 2017;20:203–207. doi: 10.4048/jbc.2017.20.2.203. PubMed DOI PMC

Jolie A. My Medical Choice. New York Times; New York, NY, USA: 2013. pp. 14–16.

Hawkes N. "Angelina effect" led to more appropriate breast cancer referrals, research shows. BMJ. 2014;349:g5755. PubMed

Rhiem K., Engel C., Graeser M., Zachariae S., Kast K., Kiechle M., Ditsch N., Janni W., Mundhenke C., Golatta M., et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high-risk families as compared to patients from BRCA1 or BRCA2 positive families: A retrospective cohort study. Breast Cancer Res. 2012;14:R156. doi: 10.1186/bcr3369. PubMed DOI PMC

Český Statistický Úřad Aktuální Populační vývoj V Kostce. Aktuální Populační Vývoj v Kostce|ČSÚ. [(accessed on 19 January 2023)]. Available online: https://www.czso.cz/csu/czso/aktualni-populacni-vyvoj-v-kostce.

Manchanda R., Gaba F., Talaulikar V., Pundir J., Gessler S., Davies M., Menon U. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66. BJOG Int. J. Obstet. Gynaecol. 2022;129:e16–e34. doi: 10.1111/1471-0528.16896. PubMed DOI PMC

Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., Garber J.E., Neuhausen S.L., Matloff E., Eeles R., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975. doi: 10.1001/jama.2010.1237. PubMed DOI PMC

Rivera C.M., Grossardt B.R., Rhodes D.J., Brown R.D., Jr., Roger V.L., Melton L.J., 3rd, Rocca W.A. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15–23. doi: 10.1097/gme.0b013e31818888f7. PubMed DOI PMC

Jakub J.W., Peled A.W., Gray R.J., Greenup R.A., Kiluk J.V., Sacchini V., McLaughlin S.A., Tchou J.C., Vierkant R.A., Degnim A.C., et al. Oncologic safety of prophylactic nipple-40sparing mastectomy in a population with BRCA1/2 mutations: A multi-institutional study. JAMA Surg. 2018;153:123–129. doi: 10.1001/jamasurg.2017.3422. PubMed DOI PMC

Stanek K., Zimovjanova M., Suk P., Jonas F., Zimovjanova A., Molitor M., Mestak O. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers. Aesthetic Plast. Surg. 2022;46:706–711. doi: 10.1007/s00266-021-02506-x. PubMed DOI

Wei C.H., Scott A.M., Price A.N., Miller H.C., Klassen A.F., Jhanwar S.M., Mehrara B.J., Disa J.J., McCarthy C., Matros E., et al. Psychosocial and sexual well-being following nipple-sparing mastectomy and reconstruction. Breast J. 2016;22:10–17. doi: 10.1111/tbj.12542. PubMed DOI PMC

Yamauchi H., Takei J. Management of hereditary breast and ovarian cancer. Int. J. Clin. Oncol. 2018;23:45–51. doi: 10.1007/s10147-017-1208-9. PubMed DOI